CTCL Clinical Trial
Official title:
A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma
This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with Large Granular Lymphocyte (LGL) Leukemia or refractory Cutaneous T-cell Lymphoma (CTCL).
This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with LGL or CTCL. The study has 5 periods: - Screening Period - 4-week Treatment Period - 3-month Treatment Extension Period - Long-term Extension Period (open-ended) - 6-week Follow-up Period Subjects will be screened for eligibility within 30 days of study Day 1 (first dosing day of the 4-Week Treatment Period). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02556463 -
A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
|
Phase 1 | |
| Withdrawn |
NCT02757248 -
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL
|
Phase 1 | |
| Recruiting |
NCT05879458 -
Ritlecitinib in CTCL
|
Phase 2 | |
| Recruiting |
NCT04087629 -
StrataCTX® as a Steroid Sparing Device
|
N/A | |
| Completed |
NCT04171791 -
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
|
Phase 1 | |
| Recruiting |
NCT03240211 -
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
|
Phase 1 |